HEZKUE® Flasche

Ready for innovation

The FIRST and ONLY
liquid sildenafil
suspension spray for ED1

HEZKUE® is tailored to individual needs and lifestyles thanks to its adjustable dosage options.

Siegel

Discreet, easy-to-carry dispenser

Graph

No water required1

Schild

Refreshing mint flavour

HEZKUE® is innovative suspension technology in a discreet, easy-to-carry dispenser2

ED, erectile dysfunction

Ready for
fast
absorption3

With HEZKUE®, all therapeutic doses are available through a single device1

5 minutes

Absorption begins within just
5 minutes*3

3x Bioavailability vs. VIAGRA® (100 mg dose 20 minutes after oral administration)**4

AUC, area under curve
Data taken from a prospective open-label, single centre, two-way crossover study to evaluate the pharmacokinetics, safety and tolerability of 100 mg of HEZKUE® and 100 mg Viagra® tablets administered orally to 52 fasted healthy male volunteers.3,4
* Data based on mean plasma concentration after application of 8 pumps of HEZKUE® (100 mg sildenafil) vs. Viagra® tablets (100 mg sildenafil). Initial absorption of HEZKUE® (100 mg of sildenafil) was observed within 5 minutes after administration (0.615 ng/mL, p=0.012) vs. Viagra® 100 mg tablets, which showed no absorption at that time. The rate of absorption was not statistically significant overall (for all timepoints). The clinical significance of this has not been evaluated. HEZKUE® should be taken approximately one hour before sexual activity.1
** In a post hoc analysis, the AUC ratio for HEZKUE® (100 mg sildenafil) was 3x higher than for Viagra® tablets (100 mg sildenafil) 20 minutes after administration (646.92 vs. 199.21, p<0.01) by Minute 20. The clinical significance of this has not been evaluated.

Ready for
flexible
dosing1

HEZKUE® delivers all therapeutic doses through a single device

The first PDE-5 inhibitor suspension in a dispenser that offers flexible dose adjustment based on individual patient needs.1

Posology1

Dosierungstabelle[1] Packung ADMINISTRATION

PDE-5, phosphodiesterase type 5
* The maximum recommended dosing frequency is once per day.1
** Prescribers should consult the Prescribing Information for further information on when a lower starting dose should be considered.1
† 20 mL of 30 mL available for administration.5

Ready for
efficacy and
safety

Sildenafil has a well-known safety profile.1
HEZKUE® showed:3

Siegel

No oral mucosal safety issues

Graph

No new safety concerns

HEZKUE®:3

Siegel

Delivers the same efficacious dose as Viagra®*1

Graph

Showed statistically significantly faster absorption rate and 3x bioavailability (AUC ratio) by 20 minutes vs. Viagra®**††,‡3,4

  • Showed statistically significantly faster absorption rate† by 20 minutes vs. Viagra®**,†,††,‡3
  • Showed 3x bioavailability (AUC ratio) by 20 minutes vs. Viagra®**,†4
  • Showed 2x absorption rate vs. Viagra® 100 mg in the first 20 minutes after oral intake**,††4

AUC, area under curve; Cmax, maximum plasma concentration Tmax, time of the maximum plasma concentration

Data taken from a prospective open-label, single centre, two-way crossover study to evaluate the pharmacokinetics, safety and tolerability of 100 mg of HEZKUE® and 100 mg Viagra® tablets administered orally to 52 fasted healthy male volunteers.3,4

*25 mg, 50 mg and 100 mg doses available in single oro-mucosal suspension spray.1
**The clinical significance of this has not been evaluated.
†In a post hoc analysis, the AUC ratio for HEZKUE® (100 mg sildenafil) was 3x higher than for Viagra®tablets (100 mg sildenafil) 20 minutes after administration (646.92 ng/mL/min vs. 199.21 ng/mL/min, p<0.01).
††The absorption rate (Cmax/Tmax) of HEZKUE® (100 mg sildenafil) was 2x that of Viagra® tablets (100 mg sildenafil) (16.00 ng/mL/min vs. 7.84 ng/mL/min, p<0.01).
‡The absorption rate (Cmax/Tmax) of HEZKUE® (100 mg sildenafil) was statistically significantly faster than that of Viagra® tablets (100 mg sildenafil) at times of 5–20 minutes. The rate of absorption was not statistically significantly faster overall (for all timepoints).

Ready to get
him ready?

Schedule a visit with a sales rep

What are you interested in?

Personal information

Your address

Preferred date

* Required

ED, erectile dysfunction

Aspargo Labs

At Aspargo Labs, we have made it our mission to revolutionise the delivery forms of medications.

With the help of our proprietary technology, we transform medications into oral suspensions – improving convenience for our patients with flexible dosing and easier application.

We have pioneered the development of a state-of-the-art dispenser that transforms the administration of medications and sets new standards for patient adherence in the healthcare industry.

HEZKUE® is indicated in adult men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance. In order for HEZKUE® to be effective, sexual stimulation is required.1 HEZKUE® should be taken approximately one hour before sexual activity.1

Adverse events should be reported. Reporting forms and information can be found at https://www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Aspargo Labs on +44 (0) 1480 465755 or safety@aspargolabs.com

Adverse event and product complaint
Part of our mission to serve patients includes collecting, reviewing and reporting of adverse events and device complaints associated with the use of Aspargo’s investigational or marketed products. Please submit all reports to:

For medical information:
Email: medinfo@cambreg.co.uk
Telephone: 01480 465755

References:

  1. HEZKUE® SmPC, November, 2024.
  2. Aspargo Labs, data on file. HEZKUE® UK patent.
  3. Kaplan SA, Moore J, Niecestro R. Int J Sci Res. 2024;13V6d:759-64.
  4. Aspargo Labs, data on file. HEZ001.
  5. HEZKUE® PI. Available at: https://www.hezkue.co.uk/sites/default/files/downloads/Hezkue-prescribing-information.pdf (Accessed May 2025).

ASP-007-001 | May 2025